Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Rhea-AI Summary
Trevi Therapeutics (Nasdaq: TRVI) will present two abstracts on oral nalbuphine extended-release (ER) for chronic cough at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain, from September 5-9, 2026.
One oral presentation will cover quality-of-life outcomes from the Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF)-related chronic cough, and one poster will address quality-of-life outcomes from the Phase 2a RIVER trial in refractory chronic cough (RCC), both using the Leicester Cough Questionnaire (LCQ).
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Q2 earnings report | Positive | +0.1% | Q2 results advanced trials and reported cash supporting development programs. |
| Jul 30 | Earnings date notice | Neutral | -0.8% | Scheduled Q2 results webcast and corporate update for August 6 at 4:30 p.m. ET. |
| Jul 28 | Conference participation | Positive | +1.7% | Announced participation in two August 2026 biotech conferences, including a fireside chat. |
| Jun 17 | Event schedule notice | Positive | +6.3% | Announced June-July attendance at BIO International and two therapeutic forums. |
| May 05 | Q1 earnings report | Positive | -2.7% | Reported Q1 results, equity proceeds, cash runway, and clinical development plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
TRVI's recent company-news reactions were mixed, with positive moves after conference and event updates but negative or near-flat reactions after earnings-related notices.
Key Terms
idiopathic pulmonary fibrosis medical
interstitial lung disease medical
extended-release technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC
NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the European Respiratory Society (ERS) Congress 2026, taking place from September 5-9, 2026, in Barcelona, Spain.
Abstract: Nalbuphine extended-release for chronic cough in patients with idiopathic pulmonary fibrosis: assessment of quality of life using the Leicester Cough Questionnaire in the Phase 2b CORAL trial
Oral Presentation Session: 325 – Moving forward in interstitial lung disease: new data on novel therapies
Date & Time: September 7, 11:00 a.m. to 12:15 p.m. CEST
Location: 3K
Oral Presenter: Marlies S. Wijsenbeek, MD, PhD
Abstract: Quality of life outcomes assessed by the Leicester Cough Questionnaire in the Phase 2a RIVER trial of nalbuphine extended-release in refractory chronic cough
Poster Session: 343 – Novel cough therapeutics: the airway microbiome
Date & Time: September 7, 12:30 p.m. to 2:00 p.m. CEST
Location: PS-15
Poster Presenter: Imran Satia, MB, BChir, PhD, MRCP
About the Phase 2b CORAL Trial
The Phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three nalbuphine ER dose groups or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo.
About the Phase 2a RIVER Trial
The Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) trial was a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, and tolerability of nalbuphine ER for the treatment of patients with RCC. Each treatment period lasted 21 days, separated by a 21-day washout period. During the nalbuphine ER treatment period, patients were titrated with assessments at 27 mg twice daily (BID), 54 mg BID, and 108 mg BID for objective cough and other assessments at each dose. The primary endpoint of the trial was the mean change in 24-hour cough frequency, as determined by an objective cough monitor, for the full analysis set (FAS) population at Day 21. The FAS population included all patients who received at least one dose of study drug and have objective cough count data on both Baseline and Day 21 in at least one treatment period.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
